Your browser doesn't support javascript.
loading
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Yu, Bo; Mao, Yicheng; Bai, Li-Yuan; Herman, Sarah E M; Wang, Xinmei; Ramanunni, Asha; Jin, Yan; Mo, Xiaokui; Cheney, Carolyn; Chan, Kenneth K; Jarjoura, David; Marcucci, Guido; Lee, Robert J; Byrd, John C; Lee, L James; Muthusamy, Natarajan.
Affiliation
  • Yu B; Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Blood ; 121(1): 136-47, 2013 Jan 03.
Article in En | MEDLINE | ID: mdl-23165478

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thionucleotides / Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / Oligonucleotides, Antisense / Nanoparticles / Antibodies, Monoclonal, Murine-Derived / Molecular Targeted Therapy / Antimetabolites, Antineoplastic Limits: Animals / Humans Language: En Journal: Blood Year: 2013 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thionucleotides / Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / Oligonucleotides, Antisense / Nanoparticles / Antibodies, Monoclonal, Murine-Derived / Molecular Targeted Therapy / Antimetabolites, Antineoplastic Limits: Animals / Humans Language: En Journal: Blood Year: 2013 Type: Article Affiliation country: United States